OC.11.7: Evaluation of M-Annheim Classification in an Italian Series of Patients Suffering From Chronic Pancreatitis

Katsotourchi, A.; Frulloni, Luca; Amodio, Antonio; Viaro, T.; Tumelero, Tiziana; Pellicciari, Mattia; Gabbrielli, Armando; Benini, Luigi; Vantini, Italo

doi:10.1016/s1590-8658(11)60220-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An Italian cohort of 302 chronic pancreatitis patients demonstrated that assigning the M-ANNHEIM clinical staging [Stage 0 (17%), Stage I (43%), Stage II (25%), Stage III (13%), Stage IV (2%)] and the M-ANNHEIM score is possible [M-ANNHEIM A (41%), B (32%), C (22%), D (7%), E (1%)], but noted that a reduction in the number of categories would facilitate the practical handling of the classification system. A correlation of singular or multiple etiologic risk factors to specific severity scores could not be ascertained ( [18]; Abstract). In 2013 a Dutch/ Danish cohort was used to investigate whether the M-ANNHEIM severity index of patients with chronic pancreatitis (60 patients) differed from healthy controls (15 patients) with respect to pain sensitivity and pain modulation.…”

Section: M-annheim Severity Index and Clinical Translationmentioning

confidence: 99%

Clinical and translational markers of severity and prognosis in chronic pancreatitis

Sirtl

Beyer

Mayerle

2022

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewThe incidence of chronic pancreatitis as a progressive inflammation and fibrosis syndrome is on the rise due to increasing awareness and improved imaging modalities. Numerous classification systems have been suggested in recent years to describe the disease, but only few of them have been used to classify the severity and prognostic significance of the disease. Biomarkers for severity and (early) chronic pancreatitis diagnosis are not yet ready for clinical application.Recent findingsIn using the M-ANNHEIM and Chronic Pancreatitis Prognosis Score (COPPS) classification system, the severity assessment and short- and medium-term disease progression is available. A prospectively validated biomarker for early chronic pancreatitis diagnosis is not yet available, metabolome-based approaches seem to have the greatest potential for clinical translation.SummaryCurrently, due to the lack of universal definition for the early disease stage of chronic pancreatitis, it is difficult to accurately classify these patient cohorts in existing scoring systems. In principle, setting up a suitable scoring system would allow surveillance and establish a therapy approaches flanked by corresponding biomarker panel development. Therapy management of chronic pancreatitis and monitoring by means of scoring systems (such as the COPPS) would make a decisive contribution to improving patient treatment.

show abstract

Section: M-annheim Severity Index and Clinical Translationmentioning

confidence: 99%

Clinical and translational markers of severity and prognosis in chronic pancreatitis

Sirtl

Beyer

Mayerle

2022

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

show abstract

“…pakāpes: vieglu, pastiprinātu, izteiktu, nozīmīgu un HP paasinājumu. M-ANNHEIM klasifikāciju lietoja HP klīniskā pētījumā, lai noskaidrotu klasifikācijas spējas izvērtēt slimības klīniskās ainas smagumu un stadiju[188]. Citā HP pētījumā M-ANNHEIM klasifikāciju veiksmīgi lietoja, lai noteiktu slimības klīniskās ainas smagumu pacientiem ar SPINK1 N34S mutāciju[191].…”

unclassified

Hroniska pankreatīta gaitas smaguma novērtēšana un kombinētā medikamentozā terapija ar pankreatīnu, protonu sūkņa inhibitoru un nesteroīdo pretiekaisuma līdzekli. Promocijas darbs

Larisa

View full text Add to dashboard Cite

The aim of the given work is to develop new assessment methods of chronic pancreatitis (CP) clinical course severity and pancreas structural change severity, and using pancreatin as monotherapy and as combination with proton pump inhibitor (PPI), as well as a combination of pancreatin, PPI and NSAID in patients with CP, to figure out the most effective medication treatment way among the ones applied.In given prospective randomized controlled study in order to appraise CP clinical course and pancreas structural change severity, some special methods were developed -Clinical pancreatic index (CPI) and Visual pancreatic index (VPI). In the study CPI and VPI were used for CP patients in case of medical treatment. Patients with CP not needing surgical or endoscopic treatment were divided in three groups, depending on the type of therapy: 1) pancreatin monotherapy group, 2) pancreatin and PPI combined therapy group and 3) pancreatin, PPI and NSAID combined therapy group.The analysis of study approved that CPI is an unbiased and a valid tool to apply for CP clinical course severity and medical treatment efficiency and prognosis assessment. In patients with CP, VPI represents pancreas structural change severity and may be useful for predicting a necessity in surgical treatment. The analysis of study results entitled to conclude that the combination of pancreatin, PPI and NSAID is the most effective in terms of improving CP clinical path and patient's quality of life, compared to pancreatin monotherapy and pancreatin combination with PPI. One month long pancreatin, PPI and NSAID combination therapy is safe for CP patients and does not cause significant side effects. This is the first CP study in Latvia and the world in which 1) the severity of CP clinical course and pancreas structural change severity are assessed integrally and quantitatively, 2) a combination of pancreatin, PPI and NSAID is used and assessed in terms of efficiency, 3) This is the first CP study in Latvia in which EORTC QLQ-C30

show abstract

OC.11.7: Evaluation of M-Annheim Classification in an Italian Series of Patients Suffering From Chronic Pancreatitis

Cited by 2 publications

References 0 publications

Clinical and translational markers of severity and prognosis in chronic pancreatitis

Clinical and translational markers of severity and prognosis in chronic pancreatitis

Hroniska pankreatīta gaitas smaguma novērtēšana un kombinētā medikamentozā terapija ar pankreatīnu, protonu sūkņa inhibitoru un nesteroīdo pretiekaisuma līdzekli. Promocijas darbs

Contact Info

Product

Resources

About